Home › Companies › SAREPTA THERAPEUTICS INC. › 2024-2025

SAREPTA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed 2025-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
478Asset managers
3,723Fund votes
2025-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SAREPTA THERAPEUTICS INC.

These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SAREPTA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Richard J. Barry	64,757,685	9,565,547	60,768	--	10,202,114	Majority: yes
Elect Director: M. Kathleen Behrens, Ph.D.	69,004,024	5,336,943	43,033	--	10,202,114	Majority: yes
Elect Director: Stephen L. Mayo, Ph.D.	73,289,653	1,051,656	42,691	--	10,202,114	Majority: yes
Elect Director: Claude Nicaise, M.D.	71,006,475	3,334,914	42,611	--	10,202,114	Majority: yes
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2024	72,144,292	2,176,998	62,710	--	10,202,114	Majority: yes
Proposal 3: Amendment to the Company's 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment	71,084,947	3,248,699	50,354	--	10,202,114	Majority: yes
Proposal 4: Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment	73,725,724	629,170	29,106	--	10,202,114	Majority: yes
Proposal 5: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2025	80,588,115	3,875,497	122,502	--	--	Majority: yes

Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-06 — read the filing on EDGAR.

How asset managers voted at the SAREPTA THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 478 asset managers that disclosed a SAREPTA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SAREPTA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 14 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 72,144,292AGAINST: 2,176,998

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2024”): 72,144,292 for, 2,176,998 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 73% for, 2% against (76% of the company cast a for/against vote).

The 468 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 98%

FOR: 98.2%AGAINST: 1.7%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	14,863,495	0	For
Vanguard	11,408,016	0	For
BlackRock	9,006,174	548	For
State Street	5,710,953	0	For
Wellington	2,881,677	0	For
T. Rowe Price	2,823,425	0	For
EcoR1 Capital, LLC	2,800,000	0	For
AMCAP FUND	2,658,367	0	For
Janus Henderson	2,465,732	0	For
Fidelity	2,449,398	0	For
Avoro Capital Advisors LLC	2,322,489	0	For
JPMorgan	2,128,877	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,816,659	0	For
JANUS INVESTMENT FUND	1,364,241	0	For
Charles Schwab	1,304,767	0	For
Aberdeen	1,268,593	0	For
Camber Capital Management LP	1,000,000	0	For
Erste Asset Management GmbH	976,000	0	For
Federated Hermes	960,859	0	For
Deep Track Capital, LP	899,731	0	For
Northern Trust	712,830	0	For
PICTET ASSET MANAGEMENT SA	700,617	0	For
MELLON INVESTMENTS Corp	667,042	0	For
John Hancock	611,425	0	For
Dimensional	416,091	0	For

Showing the 25 largest of 468 asset managers. See all 468 in the interactive database.

2. APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016, AND AMENDED ON JUNE 6, 2019 AND ON JUNE 8, 2023) (THE "2016 ESPP") TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2016 ESPP BY 300,000 SHARES TO 1,700,000 SHARES

COMPENSATIONMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 73,725,724AGAINST: 629,170

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment”): 73,725,724 for, 629,170 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 75% for, 0.7% against (76% of the company cast a for/against vote).

The 112 asset managers below cast 99.9% of the shares they voted on this item FOR (39,272,455 for, 18,186 against).

FOR 99.9%

FOR: 39,272,455 (100.0%)AGAINST: 18,186 (0.0%)ABSTAIN: 0 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	11,173,594	For
Capital Group	5,853,584	For
BlackRock	5,747,470	For
AMCAP FUND	2,658,367	For
Fidelity	2,260,022	For
State Street	1,867,371	For
JANUS INVESTMENT FUND	1,364,241	For
Erste Asset Management GmbH	976,000	For
T. Rowe Price	943,159	For
Charles Schwab	646,649	For
Aberdeen	618,314	For
Federated Hermes	446,388	For
Columbia Threadneedle	311,365	For
Jackson National	302,710	For
First Trust	301,014	For
Dimensional	276,610	For
CARILLON SERIES TRUST	249,715	For
TIAA	244,427	For
John Hancock	244,287	For
MUTUAL FUND SERIES TRUST	214,218	For
Equitable	207,173	For
AIG/SunAmerica	143,239	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	For
JPMorgan	118,548	For
Empower	109,173	For

Showing the 25 largest of 112 asset managers. See all 112 in the interactive database.

3. RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2025

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 80,588,115AGAINST: 3,875,497

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 5: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the”): 80,588,115 for, 3,875,497 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 82% for, 4% against (86% of the company cast a for/against vote).

The 111 asset managers below cast 99.7% of the shares they voted on this item FOR (39,176,548 for, 94,818 against).

FOR 99.7%

FOR: 39,176,548 (99.7%)AGAINST: 94,818 (0.2%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURREN” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	11,172,472	1,122	For
Capital Group	5,853,584	0	For
BlackRock	5,747,470	0	For
AMCAP FUND	2,658,367	0	For
Fidelity	2,260,022	0	For
State Street	1,866,769	602	For
JANUS INVESTMENT FUND	1,364,241	0	For
Erste Asset Management GmbH	976,000	0	For
T. Rowe Price	943,159	0	For
Charles Schwab	646,649	0	For
Aberdeen	618,314	0	For
Federated Hermes	446,388	0	For
Columbia Threadneedle	311,365	0	For
Jackson National	302,710	0	For
First Trust	301,014	0	For
Dimensional	276,610	0	For
CARILLON SERIES TRUST	249,715	0	For
TIAA	244,427	0	For
John Hancock	244,287	0	For
MUTUAL FUND SERIES TRUST	214,218	0	For
Equitable	207,173	0	For
AIG/SunAmerica	143,239	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	For
JPMorgan	118,548	0	For
Empower	109,173	0	For

Showing the 25 largest of 111 asset managers. See all 111 in the interactive database.

4. TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: CLAUDE NICAISE, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 71,006,475AGAINST: 3,334,914

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Claude Nicaise, M.D.”): 71,006,475 for, 3,334,914 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 72% for, 3% against (76% of the company cast a for/against vote).

The 109 asset managers below cast 99.2% of the shares they voted on this item FOR (38,965,323 for, 302,007 against).

FOR 99.1%

FOR: 38,965,323 (99.2%)AGAINST: 302,007 (0.8%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	11,173,594	0	For
Capital Group	5,853,584	0	For
BlackRock	5,747,470	0	For
AMCAP FUND	2,658,367	0	For
Fidelity	2,260,022	0	For
State Street	1,867,371	0	For
JANUS INVESTMENT FUND	1,364,241	0	For
Erste Asset Management GmbH	976,000	0	For
T. Rowe Price	823,977	119,182	For
Charles Schwab	646,649	0	For
Aberdeen	618,314	0	For
Federated Hermes	446,388	0	For
Columbia Threadneedle	311,365	0	For
Jackson National	302,710	0	For
First Trust	301,014	0	For
Dimensional	276,610	0	For
CARILLON SERIES TRUST	249,715	0	For
TIAA	244,427	0	For
John Hancock	244,287	0	For
MUTUAL FUND SERIES TRUST	214,218	0	For
Equitable	101,734	105,439	Against
AIG/SunAmerica	143,239	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	For
JPMorgan	118,548	0	For
Empower	109,173	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

5. TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: M. KATHLEEN BEHRENS, PH.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 69,004,024AGAINST: 5,336,943

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: M. Kathleen Behrens, Ph.D.”): 69,004,024 for, 5,336,943 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 70% for, 5% against (76% of the company cast a for/against vote).

The 109 asset managers below cast 96% of the shares they voted on this item FOR (37,775,746 for, 1,491,584 against).

FOR 96%

FOR: 37,775,746 (96.2%)AGAINST: 1,491,584 (3.8%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	11,172,472	1,122	For
Capital Group	5,853,584	0	For
BlackRock	5,747,470	0	For
AMCAP FUND	2,658,367	0	For
Fidelity	2,260,022	0	For
State Street	1,867,282	89	For
JANUS INVESTMENT FUND	1,364,241	0	For
Erste Asset Management GmbH	976,000	0	For
T. Rowe Price	0	943,159	Against
Charles Schwab	646,649	0	For
Aberdeen	618,314	0	For
Federated Hermes	446,388	0	For
Columbia Threadneedle	311,365	0	For
Jackson National	191,766	110,944	For
First Trust	301,014	0	For
Dimensional	276,610	0	For
CARILLON SERIES TRUST	249,715	0	For
TIAA	244,427	0	For
John Hancock	244,287	0	For
MUTUAL FUND SERIES TRUST	214,218	0	For
Equitable	101,734	105,439	Against
AIG/SunAmerica	143,239	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	For
JPMorgan	118,548	0	For
Empower	57,405	51,768	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

6. TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: RICHARD J. BARRY

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 64,757,685AGAINST: 9,565,547

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard J. Barry”): 64,757,685 for, 9,565,547 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 66% for, 10% against (76% of the company cast a for/against vote).

The 109 asset managers below cast 91% of the shares they voted on this item FOR (35,629,555 for, 3,637,775 against).

FOR 91%9%

FOR: 35,629,555 (90.7%)AGAINST: 3,637,775 (9.3%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	11,172,471	1,123	For
Capital Group	5,853,584	0	For
BlackRock	5,747,470	0	For
AMCAP FUND	2,658,367	0	For
Fidelity	2,260,022	0	For
State Street	6,074	1,861,297	Against
JANUS INVESTMENT FUND	1,364,241	0	For
Erste Asset Management GmbH	976,000	0	For
T. Rowe Price	0	943,159	Against
Charles Schwab	646,649	0	For
Aberdeen	618,314	0	For
Federated Hermes	446,388	0	For
Columbia Threadneedle	311,365	0	For
Jackson National	191,766	110,944	For
First Trust	301,014	0	For
Dimensional	276,610	0	For
CARILLON SERIES TRUST	249,715	0	For
TIAA	244,427	0	For
John Hancock	244,287	0	For
MUTUAL FUND SERIES TRUST	214,218	0	For
Equitable	101,734	105,439	Against
AIG/SunAmerica	143,239	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	For
JPMorgan	118,548	0	For
Empower	57,405	51,768	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

7. TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: STEPHEN L. MAYO, PH.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 73,289,653AGAINST: 1,051,656

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen L. Mayo, Ph.D.”): 73,289,653 for, 1,051,656 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 75% for, 1% against (76% of the company cast a for/against vote).

The 109 asset managers below cast 99.2% of the shares they voted on this item FOR (38,976,323 for, 291,007 against).

FOR 99.2%

FOR: 38,976,323 (99.2%)AGAINST: 291,007 (0.7%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR S” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	11,173,594	0	For
Capital Group	5,853,584	0	For
BlackRock	5,747,470	0	For
AMCAP FUND	2,658,367	0	For
Fidelity	2,260,022	0	For
State Street	1,867,371	0	For
JANUS INVESTMENT FUND	1,364,241	0	For
Erste Asset Management GmbH	976,000	0	For
T. Rowe Price	823,977	119,182	For
Charles Schwab	646,649	0	For
Aberdeen	618,314	0	For
Federated Hermes	446,388	0	For
Columbia Threadneedle	311,365	0	For
Jackson National	302,710	0	For
First Trust	301,014	0	For
Dimensional	276,610	0	For
CARILLON SERIES TRUST	249,715	0	For
TIAA	244,427	0	For
John Hancock	244,287	0	For
MUTUAL FUND SERIES TRUST	214,218	0	For
Equitable	101,734	105,439	Against
AIG/SunAmerica	143,239	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	For
JPMorgan	118,548	0	For
Empower	109,173	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

8. APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 PLAN BY 4,300,000 SHARES TO 17,487,596 SHARES

COMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 71,084,947AGAINST: 3,248,699

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Amendment to the Company's 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment”): 71,084,947 for, 3,248,699 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 98,254,898 outstanding shares: 72% for, 3% against (76% of the company cast a for/against vote).

The 109 asset managers below cast 99.3% of the shares they voted on this item FOR (38,021,260 for, 236,388 against).

FOR 99.3%

FOR: 38,021,260 (99.3%)AGAINST: 236,388 (0.6%)ABSTAIN: 18,186 (0.0%)NOT VOTED: 39 (0.0%)

Largest asset managers voting on “APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGG” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	11,173,594	0	0	For
Capital Group	5,853,584	0	0	For
BlackRock	5,747,470	0	0	For
AMCAP FUND	2,658,367	0	0	For
Fidelity	2,075,086	184,936	0	For
State Street	1,867,329	42	0	For
JANUS INVESTMENT FUND	1,364,241	0	0	For
T. Rowe Price	943,159	0	0	For
Charles Schwab	646,649	0	0	For
Aberdeen	618,314	0	0	For
Federated Hermes	446,388	0	0	For
Columbia Threadneedle	311,365	0	0	For
Jackson National	302,710	0	0	For
First Trust	301,014	0	0	For
Dimensional	276,610	0	0	For
CARILLON SERIES TRUST	249,715	0	0	For
TIAA	244,427	0	0	For
John Hancock	244,287	0	0	For
MUTUAL FUND SERIES TRUST	214,218	0	0	For
Equitable	207,173	0	0	For
AIG/SunAmerica	143,239	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	122,516	0	0	For
JPMorgan	118,548	0	0	For
Brighthouse	83,854	0	18,186	For
Voya	96,032	0	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

9. Amend Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 73,725,724AGAINST: 629,170

The 4 asset managers below cast 100% of the shares they voted on this item FOR (1,024,110 for, 0 against).

FOR 100%

FOR: 1,024,110 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Erste Asset Management GmbH	976,000	For
Empower	46,327	For
GuideStone	1,778	For
UNIFIED SERIES TRUST	5	For

10. Amend Stock Compensation Plan

OTHERMajority of the votes cast: yes

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 73,725,724AGAINST: 629,170

The 2 asset managers below cast 99.9% of the shares they voted on this item FOR (4,033 for, 3 against).

FOR 99.9%

FOR: 4,033 (99.9%)AGAINST: 3 (0.1%)

Largest asset managers voting on “Amend Stock Compensation Plan” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	4,033	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	0	3	0	0	Against

11. Election of Directors (Majority Voting)

DIRECTOR ELECTIONS

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at SAREPTA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	4,033	0	0	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	3	0	0	0	For

Largest SAREPTA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of SAREPTA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 98,254,898 shares outstanding at the time of that meeting.

Top SAREPTA THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Capital Group	15.13%
2	Vanguard	11.61%
3	BlackRock	9.17%
4	State Street	5.81%
5	Wellington	2.93%
6	T. Rowe Price	2.87%
7	EcoR1 Capital, LLC	2.85%
8	AMCAP FUND	2.71%
9	Janus Henderson	2.51%
10	Fidelity	2.49%

Reported SAREPTA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SAREPTA THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Shares Issued and Outstanding 4/8/2025	100.00%	DEF14A
BlackRock	10.08%	13F
Capital International Investors	9.05%	DEF14A
The Vanguard Group	8.97%	DEF14A
AQR Capital Management, LLC	8.25%	13G
Vanguard Portfolio Management	6.87%	13G
State Street	4.14%	13F
Richard J. Barry	3.29%	DEF14A
Wellington Management	2.69%	13F
Douglas S. Ingram	2.64%	DEF14A

Percentages above are of 98,254,898 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SAREPTA THERAPEUTICS INC.'s shareholder meeting held 2025-06-05, in the 2024-2025 proxy season, 478 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,723 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-06.

SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.